Cantitate/Preț
Produs

Heart Failure: Handbook of Experimental Pharmacology, cartea 243

Editat de Johann Bauersachs, Javed Butler, Peter Sandner
en Limba Engleză Hardback – 21 iun 2017
This special issue of the Handbook of Experimental Pharmacology on Heart Failure covers the entire spectrum of the field, from the current understanding and definitions of heart failure, to epidemiology and the importance of co-morbidities, clinical trial design and biomarkers, as well as imaging technologies. The main focus of this book is to review current and emerging heart failure therapies and potential targets for treatment.
Citește tot Restrânge

Toate formatele și edițiile

Toate formatele și edițiile Preț Express
Paperback (1) 171046 lei  6-8 săpt.
  Springer International Publishing – 12 mai 2018 171046 lei  6-8 săpt.
Hardback (1) 231303 lei  6-8 săpt.
  Springer International Publishing – 21 iun 2017 231303 lei  6-8 săpt.

Din seria Handbook of Experimental Pharmacology

Preț: 231303 lei

Preț vechi: 243477 lei
-5% Nou

Puncte Express: 3470

Preț estimativ în valută:
44281 48267$ 37234£

Carte tipărită la comandă

Livrare economică 18 decembrie 24 - 01 ianuarie 25

Preluare comenzi: 021 569.72.76

Specificații

ISBN-13: 9783319596587
ISBN-10: 3319596586
Pagini: 581
Ilustrații: IX, 581 p. 100 illus., 30 illus. in color.
Dimensiuni: 155 x 235 x 41 mm
Greutate: 1 kg
Ediția:1st ed. 2017
Editura: Springer International Publishing
Colecția Springer
Seria Handbook of Experimental Pharmacology

Locul publicării:Cham, Switzerland

Cuprins

Introduction.- Epidemiology.- Clinical trial design, endpoints and regulatory requirements. Biomarkers HFpEF/HFrEF. Imaging Technologies / MRI and Echo. Comorbidities in HF. Current Guideline based therapy of HFreF and HFpEF. New and Emerging Therapies and Targets. Ivabradine.- Beta3 agonists.- Novel MRAs.- pGCs and Natriuretic peptides.- sGC stimulators.- PDE’s.- Adenosin and A1 Agonists.- Myosin heavy chain / Troponin.- Stem cells.- Diuretics and Vasopressin.- GeneTherapy.- RNA-based therapies and micro RNAs.- Cardiac myosin activation using gene therapy.- Bendavia – mitochondrial therapies.- WNT signaling.- Anticoagulation therapy and NOACS in HF.- Potassium Binders.- Iron.           

Caracteristici

Comprehensive and state of the art overview of current and emerging heart failure treatments Up to date information on treatment guidelines and clinical trials in heart failure Authorships of worldwide heart failure experts from both academia and industry